<ul>
<li>異常高的交易量指向這些股票的上漲潛力</li>
</ul>
<p>Candel Therapeutics, Inc.（NASDAQ:CADL - 免費報告）- Brookline Capital Management 的股票分析師在 2023 年 12 月 7 日（星期日）發佈的報告中發佈了 Candel Therapeutics 的 2025 年第四季度收益預估。Brookline Capital Management 的分析師 K. Dolliver 預計該公司本季度每股收益為（$0.22）。Candel Therapeutics 當前全年的共識收益預估為每股（$1.47）。</p>
<p>獲取 <strong>Candel Therapeutics</strong> 的提醒：</p>
<p>其他幾家券商最近也發佈了關於 CADL 的報告。Lifesci Capital 在 2023 年 10 月 21 日（星期二）對 Candel Therapeutics 進行了覆蓋。他們對該股票給予了 “跑贏大盤” 的評級，並設定了$16.00 的目標價。花旗集團在 2023 年 11 月 14 日（星期五）將 Candel Therapeutics 的目標價從$25.00 下調至$24.00，並對該股票設定了 “買入” 評級。Stephens 在週一重新發布了 “增持” 評級，並對 Candel Therapeutics 的股票設定了$15.00 的目標價。美國銀行在 2023 年 9 月 3 日（星期三）將 Candel Therapeutics 的股票評級從 “買入” 下調至 “中性”，並將該股票的目標價從$13.00 下調至$7.00。最後，Wall Street Zen 在 2023 年 11 月 15 日（星期六）的研究報告中將 Candel Therapeutics 的股票評級從 “持有” 下調至 “賣出”。一位股票研究分析師對該股票給予了強烈買入評級，五位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Candel Therapeutics 目前的共識評級為 “適度買入”，共識目標價為$18.33。</p>
<p><strong>查看我們對 Candel Therapeutics 的最新股票分析</strong></p>
<h2>Candel Therapeutics 的價格表現</h2>
<p>NASDAQ:CADL 的股票在週三開盤價為$5.66。該公司的市值為$3.1073 億，市盈率為-9.93，貝塔值為-0.92。Candel Therapeutics 的 52 周低點為$4.25，52 周高點為$14.60。該公司的債務與股本比率為 0.01，速動比率為 8.25，流動比率為 8.25。該公司的 50 日移動平均價格為$5.22，200 日移動平均價格為$5.50。</p>
<p>Candel Therapeutics（NASDAQ:CADL - 獲取免費報告）最近在 2023 年 11 月 13 日（星期四）發佈了季度收益結果。該公司報告本季度每股收益為（$0.21），低於分析師的共識預估（$0.17）$0.04。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近增加或減少了在 CADL 的持股。BNP Paribas Financial Markets 在第三季度將其在 Candel Therapeutics 的持股增加了 128.2%。BNP Paribas Financial Markets 現在擁有 7901 股該公司的股票，價值$40,000，在此期間又購買了 4439 股。Tower Research Capital LLC TRC 在第二季度將其在 Candel Therapeutics 的持股增加了 361.7%。Tower Research Capital LLC TRC 現在擁有 9608 股該公司的股票，價值$49,000，在此期間又購買了 7527 股。Invesco Ltd.在第一季度購買了 Candel Therapeutics 的新股份，價值$59,000。AlphaQuest LLC 在第一季度購買了 Candel Therapeutics 的新股份，價值$61,000。最後，Taylor Financial Group Inc.在第三季度將其在 Candel Therapeutics 的持股增加了 36.0%。Taylor Financial Group Inc.現在擁有 13600 股該公司的股票，價值$69,000，在上個季度又獲得了 3600 股。對沖基金和其他機構投資者持有該公司 13.93% 的股票。</p>
<h2>Candel Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Candel Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於為癌症患者開發免疫療法。它開發的 CAN-2409 目前正在進行針對胰腺癌的二期臨牀試驗；針對前列腺癌的三期臨牀試驗；以及針對肺癌的二期臨牀試驗，並已完成針對高等級膠質瘤的 Ib/II 期臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Candel Therapeutics 更好</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>內部人士正在出售這三隻股票——原因在這裏</li>
<li>道瓊斯的狗策略是什麼？概述和示例</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>股票市場升級：它們是什麼？</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年前爆炸</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Candel Therapeutics 嗎？</h2>
<p>在你考慮 Candel Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Candel Therapeutics 並不在名單上。</p>
<p>雖然 Candel Therapeutics 目前在分析師中有適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CADL

<p>Brookline Capital Management 預計 Candel Therapeutics 在 2025 年第四季度每股收益為（$0.22）。該股票的共識評級為 “適度買入”，目標價格為 $18.33。最近的評級包括 “跑贏大盤” 和 “買入”，但美國銀行將其下調至 “中性”。機構投資者已調整其持股比例，對沖基金持有該股票的 13.93%。Candel Therapeutics 開發癌症免疫療法，目前有多個正在進行的臨牀試驗</p>

<ul>
<li>Unusually High Volume Points to Upside in These Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>異常高的交易量指向這些股票的上漲潛力</li>
</ul>
</div><p>Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday, December 7th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.22) per share for the quarter. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share.</p>
<div class="lb-trans"><p>Candel Therapeutics, Inc.（NASDAQ:CADL - 免費報告）- Brookline Capital Management 的股票分析師在 2023 年 12 月 7 日（星期日）發佈的報告中發佈了 Candel Therapeutics 的 2025 年第四季度收益預估。Brookline Capital Management 的分析師 K. Dolliver 預計該公司本季度每股收益為（$0.22）。Candel Therapeutics 當前全年的共識收益預估為每股（$1.47）。</p>
</div><p>Get <strong>Candel Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Candel Therapeutics</strong> 的提醒：</p>
</div><p>Several other brokerages have also recently issued reports on CADL. Lifesci Capital assumed coverage on Candel Therapeutics in a report on Tuesday, October 21st. They issued an &#34;outperform&#34; rating and a $16.00 target price on the stock. Citigroup decreased their price objective on Candel Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, November 14th. Stephens reissued an &#34;overweight&#34; rating and issued a $15.00 target price on shares of Candel Therapeutics in a report on Monday. Bank of America cut shares of Candel Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and reduced their price target for the stock from $13.00 to $7.00 in a research report on Wednesday, September 3rd. Finally, Wall Street Zen lowered shares of Candel Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Candel Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $18.33.</p>
<div class="lb-trans"><p>其他幾家券商最近也發佈了關於 CADL 的報告。Lifesci Capital 在 2023 年 10 月 21 日（星期二）對 Candel Therapeutics 進行了覆蓋。他們對該股票給予了 “跑贏大盤” 的評級，並設定了$16.00 的目標價。花旗集團在 2023 年 11 月 14 日（星期五）將 Candel Therapeutics 的目標價從$25.00 下調至$24.00，並對該股票設定了 “買入” 評級。Stephens 在週一重新發布了 “增持” 評級，並對 Candel Therapeutics 的股票設定了$15.00 的目標價。美國銀行在 2023 年 9 月 3 日（星期三）將 Candel Therapeutics 的股票評級從 “買入” 下調至 “中性”，並將該股票的目標價從$13.00 下調至$7.00。最後，Wall Street Zen 在 2023 年 11 月 15 日（星期六）的研究報告中將 Candel Therapeutics 的股票評級從 “持有” 下調至 “賣出”。一位股票研究分析師對該股票給予了強烈買入評級，五位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Candel Therapeutics 目前的共識評級為 “適度買入”，共識目標價為$18.33。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Candel Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Candel Therapeutics 的最新股票分析</strong></p>
</div><h2>Candel Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Candel Therapeutics 的價格表現</h2>
</div><p>Shares of NASDAQ:CADL opened at $5.66 on Wednesday. The firm has a market cap of $310.73 million, a price-to-earnings ratio of -9.93 and a beta of -0.92. Candel Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $14.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.25 and a current ratio of 8.25. The firm has a fifty day moving average price of $5.22 and a 200 day moving average price of $5.50.</p>
<div class="lb-trans"><p>NASDAQ:CADL 的股票在週三開盤價為$5.66。該公司的市值為$3.1073 億，市盈率為-9.93，貝塔值為-0.92。Candel Therapeutics 的 52 周低點為$4.25，52 周高點為$14.60。該公司的債務與股本比率為 0.01，速動比率為 8.25，流動比率為 8.25。該公司的 50 日移動平均價格為$5.22，200 日移動平均價格為$5.50。</p>
</div><p>Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04).</p>
<div class="lb-trans"><p>Candel Therapeutics（NASDAQ:CADL - 獲取免費報告）最近在 2023 年 11 月 13 日（星期四）發佈了季度收益結果。該公司報告本季度每股收益為（$0.21），低於分析師的共識預估（$0.17）$0.04。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in CADL. BNP Paribas Financial Markets boosted its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock valued at $40,000 after buying an additional 4,439 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after purchasing an additional 7,527 shares during the period. Invesco Ltd. purchased a new stake in shares of Candel Therapeutics in the 1st quarter worth $59,000. AlphaQuest LLC bought a new position in shares of Candel Therapeutics during the 1st quarter worth $61,000. Finally, Taylor Financial Group Inc. raised its holdings in shares of Candel Therapeutics by 36.0% in the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company's stock valued at $69,000 after acquiring an additional 3,600 shares in the last quarter. Hedge funds and other institutional investors own 13.93% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近增加或減少了在 CADL 的持股。BNP Paribas Financial Markets 在第三季度將其在 Candel Therapeutics 的持股增加了 128.2%。BNP Paribas Financial Markets 現在擁有 7901 股該公司的股票，價值$40,000，在此期間又購買了 4439 股。Tower Research Capital LLC TRC 在第二季度將其在 Candel Therapeutics 的持股增加了 361.7%。Tower Research Capital LLC TRC 現在擁有 9608 股該公司的股票，價值$49,000，在此期間又購買了 7527 股。Invesco Ltd.在第一季度購買了 Candel Therapeutics 的新股份，價值$59,000。AlphaQuest LLC 在第一季度購買了 Candel Therapeutics 的新股份，價值$61,000。最後，Taylor Financial Group Inc.在第三季度將其在 Candel Therapeutics 的持股增加了 36.0%。Taylor Financial Group Inc.現在擁有 13600 股該公司的股票，價值$69,000，在上個季度又獲得了 3600 股。對沖基金和其他機構投資者持有該公司 13.93% 的股票。</p>
</div><h2>Candel Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Candel Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.</p>
<div class="lb-trans"><p>Candel Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於為癌症患者開發免疫療法。它開發的 CAN-2409 目前正在進行針對胰腺癌的二期臨牀試驗；針對前列腺癌的三期臨牀試驗；以及針對肺癌的二期臨牀試驗，並已完成針對高等級膠質瘤的 Ib/II 期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Candel Therapeutics</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Insiders Are Selling These 3 Stocks—Here’s Why</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>Stock Market Upgrades: What Are They?</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Candel Therapeutics 更好</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>內部人士正在出售這三隻股票——原因在這裏</li>
<li>道瓊斯的狗策略是什麼？概述和示例</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>股票市場升級：它們是什麼？</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年前爆炸</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Candel Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Candel Therapeutics 嗎？</h2>
</div><p>Before you consider Candel Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Candel Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Candel Therapeutics 並不在名單上。</p>
</div><p>While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Candel Therapeutics 目前在分析師中有適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Brookline Capital Management 對 CADL 第四季度財報發表看法